XML 16 R6.htm IDEA: XBRL DOCUMENT v3.23.3
CONSOLIDATED STATEMENTS OF EQUITY - USD ($)
$ in Thousands
Total
Total Lisata Therapeutics, Inc. Stockholders' Equity
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Loss
Accumulated Deficit
Treasury Stock
Non- Controlling Interest in Subsidiary
Common stock, beginning balance (in shares) at Dec. 31, 2021     3,986,000          
Beginning balance at Dec. 31, 2021 $ 92,000 $ 92,254 $ 4 $ 546,044 $ (70) $ (453,016) $ (708) $ (254)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net loss (48,235) (48,235)       (48,235)    
Share-based compensation (in shares)     100,000          
Share-based compensation 1,899 1,899   1,899        
Net proceeds from issuances of common stock (in shares)     4,000          
Net proceeds from issuances of common stock 29 29   29        
Issuance of common stock in connection with Merger (in shares)     3,773,000          
Issuance of common stock in connection with Merger 26,098 26,098 $ 4 26,094        
Unrealized gain on marketable securities 5 5     5      
Foreign currency translation adjustment (25) (25)     (25)      
Common stock, ending balance (in shares) at Sep. 30, 2022     7,863,000          
Ending balance at Sep. 30, 2022 71,771 72,025 $ 8 574,066 (90) (501,251) (708) (254)
Common stock, beginning balance (in shares) at Jun. 30, 2022     4,038,000          
Beginning balance at Jun. 30, 2022 82,137 82,391 $ 4 547,032 (70) (463,868) (708) (254)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net loss (37,383) (37,383)       (37,383)    
Share-based compensation (in shares)     52,000          
Share-based compensation 939 939   940        
Issuance of common stock in connection with Merger (in shares)     3,773,000          
Issuance of common stock in connection with Merger 26,098 26,098 $ 4 26,094        
Unrealized gain on marketable securities 5 5     5      
Foreign currency translation adjustment (25) (25)     (25)      
Common stock, ending balance (in shares) at Sep. 30, 2022     7,863,000          
Ending balance at Sep. 30, 2022 $ 71,771 72,025 $ 8 574,066 (90) (501,251) (708) (254)
Common stock, beginning balance (in shares) at Dec. 31, 2022 7,866,061   7,867,000          
Beginning balance at Dec. 31, 2022 $ 66,324 66,578 $ 8 574,548 (29) (507,241) (708) (254)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Proceeds from option exercises (in shares) 1,227,776              
Common stock, ending balance (in shares) at Jun. 30, 2023     8,133,000          
Ending balance at Jun. 30, 2023 $ 57,714 57,968 $ 8 576,173 (50) (517,455) (708) (254)
Common stock, beginning balance (in shares) at Dec. 31, 2022 7,866,061   7,867,000          
Beginning balance at Dec. 31, 2022 $ 66,324 66,578 $ 8 574,548 (29) (507,241) (708) (254)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net loss (15,475) (15,475)       (15,475)    
Share-based compensation (in shares)     114,000          
Share-based compensation 1,474 1,474   1,474        
Net proceeds from issuances of common stock (in shares)     76,000          
Net proceeds from issuances of common stock $ 297 297   297        
Proceeds from option exercises (in shares) 82,500   83,000          
Proceeds from option exercises $ 155 155   155        
Unrealized gain on marketable securities 1 1     1      
Foreign currency translation adjustment $ (72)       (72)      
Common stock, ending balance (in shares) at Sep. 30, 2023 8,139,449   8,140,000          
Ending balance at Sep. 30, 2023 $ 52,704 52,958 $ 8 576,474 (100) (522,716) (708) (254)
Common stock, beginning balance (in shares) at Jun. 30, 2023     8,133,000          
Beginning balance at Jun. 30, 2023 57,714 57,968 $ 8 576,173 (50) (517,455) (708) (254)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net loss (5,261) (5,261)       (5,261)    
Share-based compensation (in shares)     7,000          
Share-based compensation 301 301   301        
Foreign currency translation adjustment $ (50) (50)     (50)      
Common stock, ending balance (in shares) at Sep. 30, 2023 8,139,449   8,140,000          
Ending balance at Sep. 30, 2023 $ 52,704 $ 52,958 $ 8 $ 576,474 $ (100) $ (522,716) $ (708) $ (254)